Vista Pharmaceuticals Ratios

Vista Pharmaceuticals Ltd Ratios

The Vista Pharmaceuticals Ltd Ratios page provides a complete fundamental analysis of Vista Pharmaceuticals Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Vista Pharmaceuticals Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Vista Pharmaceuticals Ltd (NSE: , BSE: 524711) is currently trading at ₹7.50, with a market capitalization of ₹461.64M. As a major player in the Health technology sector and Pharmaceuticals: major industry, Vista Pharmaceuticals Ltd remains a key stock for fundamental analysis using Vista Pharmaceuticals Ltd Ratios.

Vista Pharmaceuticals Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Vista Pharmaceuticals Ltd P/E ratio currently stands at 0, making it one of the most tracked metrics in Vista Pharmaceuticals Ltd Ratios.

Historically, the Vista Pharmaceuticals Ltd P/E ratio has shown strong fluctuations:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0
• 2020: 0

The decline in Vista Pharmaceuticals Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Vista Pharmaceuticals Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 1.46.

Historical P/B trend:

• 2024: 1.46
• 2023: 1.24
• 2022: 0.86
• 2021: 0.96

Vista Pharmaceuticals Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Vista Pharmaceuticals Ltd P/S ratio currently stands at 6.27, an important part of Vista Pharmaceuticals Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 6.27
• 2023: 4.52
• 2022: 30.68
• 2021: 85.97

The rising Vista Pharmaceuticals Ltd P/S ratio indicates improved revenue valuation by investors.

Vista Pharmaceuticals Ltd Price to Cash Flow Ratio (P/CF)

The Vista Pharmaceuticals Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.

Historical Vista Pharmaceuticals Ltd Price to Cash Flow Ratio:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0
• 2020: 0

The declining Vista Pharmaceuticals Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Vista Pharmaceuticals Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Vista Pharmaceuticals Ltd EV currently stands at ₹698.22M, representing the total company valuation including debt.

Historical EV trend:

• 2024: 698.22M
• 2023: 544.18M
• 2022: 405.49M
• 2021: 464.03M

Vista Pharmaceuticals Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Vista Pharmaceuticals Ltd EV/EBITDA ratio is currently 0, a key metric in Vista Pharmaceuticals Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0

Stable Vista Pharmaceuticals Ltd EV/EBITDA indicates balanced valuation.

Vista Pharmaceuticals Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Vista Pharmaceuticals Ltd D/E ratio is currently 0.16, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.16
• 2023: 0.20
• 2022: 0.27
• 2021: 0.35

Vista Pharmaceuticals Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Vista Pharmaceuticals Ltd ROE currently stands at -10.83%, showing profitability and capital efficiency.

Historical ROE:

• 2024: -10.83
• 2023: -11.69
• 2022: -15.69
• 2021: -2.60

Declining ROE indicates pressure on profitability.

Vista Pharmaceuticals Ltd Ratios Analysis Summary

The Vista Pharmaceuticals Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Vista Pharmaceuticals Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Vista Pharmaceuticals Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.